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The fragile histidine triad (FHIT) gene is frequently inactivated in various types of tumours. However, the system-wide pathology
caused by FHIT inactivation has not been examined in detail. Here we demonstrate that Fhit gene knockout mice develop tumours in
the lymphoid tissue, liver, uterus, testis, forestomach and small intestine, together with structural abnormalities in the small intestinal
mucosa. These results suggest that Fhit plays important roles in systemic tumour suppression and in the integrity of mucosal structure
of the intestines.
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The fragile histidine triad (FHIT) gene has been identified as a
candidate tumour suppressor gene localized in FRA3B, the most
sensitive common fragile site, at chromosome 3p14.2 (Ohta et al,
1996). Chromosomal deletion of the FHIT-containing locus or
inactivation of FHIT is frequently observed in various types of
cancers (for a review, see Huebner and Croce, 2003), consistent
with a tumour suppressor function in a variety of organs. The Fhit
protein carries a proapoptotic activity through a caspase-
dependent pathway in human cancer cells, which may contribute
to the tumour suppressor activity (Ji et al, 1999; Ishii et al, 2001;
Roz et al, 2002).
Previously, we have demonstrated that Fhit mutant mice
develop tumours spontaneously in lymphatic tissues, sebaceous
glands, liver, stomach, colonic submucosa, uterus, skin, salivary
glands, and parathyroid glands (Zanesi et al, 2001). Moreover, Fhit
knockout mice are susceptible to chemical carcinogen-induced
tumour formation in the forestomach (Fong et al, 2000), which is
reversed by adenoviral transduction of the human FHIT gene
(Dumon et al, 2001). These results are consistent with the tumour
suppressor function of FHIT. To further characterise tissue types
affected by inactivation of Fhit, including nontumorous lesions, we
have constructed a second mouse strain with a targeted Fhit gene,
and conducted a thorough pathological analysis. These Fhit
mutant mice develop tumours in a variety of tissues, including
intestinal adenomatous polyps, and show abnormal tissue building
of intestinal mucosa, suggesting avenues for further study of Fhit
function in normal tissues.
MATERIALS AND METHODS
All in vivo experiments were carried out with ethical committee
approval and met the standards required by the UKCCCR
guidelines (Workman et al, 1998). The mouse Fhit gene-targeting
vector was constructed to replace exon 5, containing the
translation initiation codon, with a pGK-Neo-bpA cassette.
Homologous recombination in ES cells (RW4) was confirmed by
genomic Southern hybridisation (data not shown). Germline
transmitted F1 (þ/ ) mice were intercrossed to obtain Fhit
(þ/þ), (þ/ ) and ( / ) progeny. Both males and females of
each genotype from 12 to 20 months of age were used for thorough
pathological examinations. Tissue samples were first examined
under a dissection microscope. Then, all tissues were fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS) for 16h at
41C, embedded in paraffin wax, sectioned at 4mm thickness and
stained with H&E. For immunostaining, sections were preincu-
bated with 3% BSA/10% goat serum in PBS for 2h and incubated
with anti-b-catenin antibody (Sigma Chemical Co., St Louis, MO,
USA) at 5000-fold dilution or with c-Kit antibody (Santa Cruz, CA,
USA) at 400-fold. Signals were visualised using the Vectastain Elite
Kit (Vector Laboratories, Burlingame, CA, USA). For mutation
analysis and microsatellite instability (MSI) analysis, DNA samples
were extracted from paraffin-embedded sections using DEXPAT
(TaKaRa, Japan). Extracted DNA samples were subjected to PCR in
11 contiguous fragments spanning nucleotides 2750–4830 of exon
15 of the Apc gene, where germline and somatic mutations were
frequently detected. Amplified DNA samples were sequenced
directly with the respective primers using the BigDye Terminator
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sCycle Sequencing Ready Reaction Kit (Applied Biosystems;
Rotkreuz, Switzerland) and ABI Prism 377 DNA Sequencing
System (Applied Biosystems). For MSI analysis, four primer sets,
D1Mit4, D6Mit59, D9Mit67 and D10Mit2 (http://www.informa-
tics.jax.org), were used. DNA samples extracted from polyps were
amplified by PCR. After denaturation (1001C, 5min), PCR
products were loaded onto 5% Long Ranger Gel (TaKaRa) in 8 M
urea, and electrophoresed at 150V for 40min. The dried gel was
scanned in a BAS-1800 (Fujifilm, Japan).
RESULTS AND DISCUSSION
Fhit (þ/ ) and ( / ) mice were viable, fertile and clinically
normal up to 12 months of age. However, upon necropsy, tumours
and abnormal lesions were found in mice older than 12 months,
consistent with observations of another Fhit mutant strain (Fong
et al, 2000). Although several types of tumours developed
spontaneously even in the age-matched wild-type littermates,
overall incidences of tumours and abnormal lesions were
significantly higher in both Fhit (þ/ ) and ( / ) mice than in
the wild-type littermates (60, 77 and 30% in Fhit (þ/ ), ( / )
and (þ/þ) mice, respectively; Table 1). In both Fhit (þ/ ) and
( / ) mice, lymphoid malignancies including B-cell lymphoma
and lymphocyte infiltrations, hemangioma and adenoma of the
liver, and uterine leiomyoma were found, which is consistent with
the previous report (Zanesi et al, 2001). Gastrointestinal stromal
tumour (GIST) was described in the other Fhit mutant strain. Here,
we have confirmed the diagnosis by immunohistochemistry for
c-Kit protein (Figure 1A inset). In the present study, several
additional types of tumours were detected, such as Leydig cell
tumour, endometrial hyperplasia and hepatocellular carcinoma
(Table 1). However, the last two tumours were observed also in
Fhit (þ/þ) mice, and no increase was found in incidence in Fhit
mutant mice for either tumour type. One Leydig cell tumour was
observed in one of 90 Fhit (þ/ ) mice (Figure 1B), although the
number is too small to draw a statistical link with Fhit deficiency,
and none was found in ( / ) animals.
Interestingly, some adenomatous polyps were found in the small
intestine of Fhit mutant mice (Figure 1C, D), whereas these polyps
have never been observed in wild-type littermates (Table 1).
Although the incidence of polyp development in Fhit ( / ) was
higher (15.4%) than that in Fhit (þ/ ) mice (6.7%), the polyp
multiplicity was not different in the two genotypes. These results
suggest that tumours develop in Fhit (þ/ ) mice because of
Fhit haploinsufficiency, either directly or through an indirect
mechanism.
Mutations in the gene encoding Apc or b-catenin result in
intestinal adenomatous polyposis through Wnt signalling activa-
tion (Oshima et al, 1995; Harada et al, 1999). To examine whether
the Wnt pathway was activated in the intestinal polyps of Fhit-
deficient mice, we localised b-catenin in nine polyp tissues from
both Fhit (þ/ ) and Fhit ( / ) mice by immunohistochemistry.
b-Catenin had accumulated in the nucleus in two polyps of Fhit
(þ/ ) mice, indicating Wnt activation in these adenoma cells
(Figure 1E). b-Catenin was localised to the basolateral side of
adenoma cells in the other seven polyps (Figure 1F). By sequence
Table 1 Tumour and abnormality incidence and tumour spectrum
Histological tumour types
Genotype n
a
Age
(months)
Incidence of tumours
and/or abnormal
lesions (% of animals)
Intestinal lesions
(% of animals)
Forestomach
papilloma
Lymphoid
malignancies
Other
neoplasms
Fhit (+/+) 26 12–20 8 (30%) 0 3 (12%) 3 (12%) 1 hepatocellular carcinoma
2 lymphomas (1 B-cell lymphoma) 1 periosis hepatis
1 lymphocyte infiltration 1 endometrial hyperplasia
Fhit (+/–) 90 12–20 54 (60%)
b 19 (21%) 22 (24%) 23 (26%) 1 hepatocellular carcinoma
6 small intestinal polyps 18 lymphomas (16 B-cell lymphomas) 1 hepatocellular adenoma
5 fused villi 5 lymphocyte infiltrations 1 liver hemangioma
8 swollen crypts 2 endometrial hyperplasia
1 uterine leiomyoma
1 lung adenoma
1 Leydig cell tumour
1 dermoid cyst
Fhit (–/–) 26 12–20 20 (77%)
b 7
c (27%) 6 (23%) 11 (42%) 2 hepatocellular carcinomas
4 small intestinal polyps 9 lymphomas (6 B-cell lymphomas) 2 endometrial hyperplasia
3 fused villi 2 lymphocyte infiltrations 1 GIST
d
1 swollen crypts
aNumber of animals.
bPo0.05 compared to wild-type controls by chi-squared test.
cOne of these mice contained a small intestinal polyp and a fused villi. The other mice
contained only one lesion per mouse.
dGastrointestinal stromal tumour.
Figure 1 Histology of tumours and abnormal intestinal mucosa in Fhit-deficient mice. (A) Gastrointestinal stromal tumour in a female Fhit ( / ) mouse at
20 months of age. Inset, immunostaining with an anti-c-Kit antibody. (B) Leydig cell tumour in a male Fhit (þ/ ) mouse at 15 months. (C) Dissection
micrograph of a duodenal polyp in a Fhit ( / ) mouse at 15 months. (D) Schematic distribution of the small intestinal polyps. Asterisks indicate relative
locations of the polyps. (E, F) Immunostaining for b-catenin in polyps of a Fhit (þ/ ) mouse at 12 months, and Fhit ( / ) at 15 months, respectively. Note
the nuclear accumulation of b-catenin (white arrowheads) in (E) and basolateral staining (asterisks) in (F). (G, J) Dissection micrographs of swollen crypts
(ileum) in a Fhit (þ/ ) mouse at 20 months, and fused villi (duodenum) in a Fhit (þ/ ) at 20 months, respectively. (H, K) Normal ileal mucosa adjacent to
the lesions shown in (I, L), respectively. (I, L) Histological sections of ileal swollen crypts in a Fhit (þ/ ) mouse at 20 months, and fused villi in a Fhit (þ/ )
at 20 months, respectively. Bars in: (A) 500mm; (B) 100mm; (C) 250mm; (E, F)5 0mm; (G, J) 250mm; (H, I, K, L) 200mm.
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polyps, we further found a nonsense mutation in the Apc gene at
codon 1055 (wt: GAA (Glu)-mutant: TAA (STOP)) in one polyp.
This mutation may explain the cause of at least a fraction of the
polyps, although other genes may be mutated giving rise to other
adenomas. As the intestines were not inspected in detail in the
other Fhit knockout strain, it is conceivable that similar intestinal
lesions existed at low frequencies. These results suggest that an
insufficient Fhit level can induce Apc gene mutations, which is
consistent with the enhanced survival and mutation frequency of
Fhit-deficient cells after UVC or mitomycin C damage (Ottey et al,
2004). In contrast, MSI was not observed in genomic DNAs from
Fhit mutant mouse tails or tumours (Fong et al, 2000). In the
present study, we also examined MSI in cells from two intestinal
polyps, using four different sets of markers, and confirmed no MSI
in these samples (data not shown). Accordingly, it is possible that
inactivation of Fhit results in tumorigenesis through induction of
mutations in tumour suppressor genes.
On the other hand, morphological abnormalities in the small
intestine, such as swollen crypts (goblet cell hyperplasia, Figure
1G, H) and fused villi (aggregated villi, Figure 1I, J), were observed
in both Fhit (þ/ ) and ( / ) mice at similar incidences. Such
lesions were not found in the age-matched wild-type mice.
Histologically, these lesions consisted of differentiated epithelial
cells without any signs of dysplasia. Thus, it is conceivable that
Fhit expression is necessary also for the maintenance of normal
intestinal architecture, in addition to suppressing tumorigenesis.
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